TMThomas H. A. Meath

Thomas H. A. Meath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas H. A. Meath has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variation in time to payment in Medicaid managed care: evidence from national TAF data, 2022

    by Jane M Zhu, Thomas H A Meath, Nataniel Moreau, K John McConnell, Susan H Busch, Chima D Ndumele

    Background: Timely payment of Medicaid claims is critical for provider cash flow, administrative burden, and participation in managed care networks. Although federal and state prompt-pay standards apply to Medicaid managed care organizations (MCOs), national evidence on payment timeliness remains limited. Methods: Using 2022 national Transformed Medicaid Statistical Information System (TAF) claims data, we examined time to payment for professional and ancillary services inclusive of time associated with provider billing and subsequent payer reimbursement, billed to Medicaid MCOs in 39 states and the District of Columbia. We characterized claim-level payment distributions, service-specific patterns, and variation across MCOs and states. We estimated state and MCO fixed-effects models to assess the share of variation attributable to plan- vs state-level differences. Results: Median time to payment was 26 days (interquartile range, 32 days), with 90% of all professional claims paid within 128 days. Payment times were similar across most selected service types but varied across MCOs and states. While plans paid most claims within 30 days, 53 MCOs paid more than 25% of claims at or beyond 90 days, and 8 MCOs paid more than half of claims after 90 days. Conclusions: Time to payment can be substantial and in some cases, takes several months, with important implications for provider participation, oversight, and network stability.

  • The Spillover Effect of the Medicare Mandatory Bundled Payment Program on Joint Replacement Outcomes

    by Hyunjee Kim, Kyle D. Hart, Thomas H.A. Meath, Jane M. Zhu, K. John McConnell

    Background: To improve the value and efficiency of care among traditional Medicare enrollees, the Centers for Medicare & Medicaid Services has implemented alternative payment models designed to control health-care spending and improve quality. These models may affect care beyond traditional Medicare enrollees, “spilling over” into other populations. Established in April 2016, the Medicare mandatory bundled payment program, called the Comprehensive Care for Joint Replacement (CJR) model, holds hospitals accountable for spending and quality of care for traditional Medicare joint-replacement patients during care episodes that span from the index hospitalization to 90 days post-discharge. We assessed the extent to which the CJR model was associated with outcomes for patients enrolled in commercial insurance and Medicare Advantage plans. Methods: With use of Health Care Cost Institute claims data from 2012 through 2017, we assessed the association of the CJR model with total expenditures, discharges to institutional post-acute care, and readmissions among commercial insurance and Medicare Advantage joint-replacement patients. The exposure variable was the implementation of the CJR model in 67 randomly selected metropolitan statistical areas compared with 103 similar areas without CJR implementation. We utilized difference-in-differences models to estimate the spillover effects of the CJR model by comparing outcomes between these areas before and after CJR implementation. Results: The study included 174,893 joint-replacement episodes of care in commercial insurance enrollees and 202,070 episodes in Medicare Advantage enrollees. Among both commercial insurance and Medicare Advantage enrollees, CJR implementation was associated with no meaningful changes in total episode expenditures, discharges to institutional post-acute care, or readmissions. Conclusions: We found no evidence for spillover effects of the CJR model on commercial insurance and Medicare Advantage patients, suggesting that alternative payment models targeting traditional Medicare patients may have limited effects on the cost and quality of care for patients outside of the traditional Medicare system.


  • Association of rural location and long acting reversible contraceptive use among Oregon Medicaid recipients

    by Maria I. Rodriguez, Thomas Meath, Jiaming Huang, Blair G. Darney, K. John McConnell


  • Open Access

    Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified

    by Jessica J. Wyse, Benjamin J. Morasco, Steven K. Dobscha, Bs Michael I. Demidenko, Thomas H. A. Meath, Travis I. Lovejoy

    Objective: Urine drug testing (UDT) is increasingly performed as a means of identifying aberrant behavior that may be grounds for discontinuation of long-term opioid therapy (LTOT). Little is known, however, about the ways in which positive UDT results may differentially inform decisions to discontinue LTOT based on the type of substance for which the UDT screened positive. The aim of this study was to examine the likelihood of clinician-initiated discontinuation of LTOT attributed to positive UDT results across three discrete categories of substances: (1) cannabis, (2) alcohol or illicit substances (excluding cannabis), and (3) controlled prescription medications that were not prescribed.Design: This retrospective study utilized the US Department of Veterans Affairs (VA) Health Care System. Corporate Data Warehouse to assemble a sample of 600 patients with substance use disorders and matched controls who were discontinued from LTOT in 2012. Comprehensive manual medical record review identified UDT results in the year prior to discontinuation and reason(s) for discontinuation.Patients, Participants: Patients with one or more UDTs positive for a single substance (N = 185) comprised the study sample.Main Outcome Measure(s): Likelihood of clinician-initiated discontinuation attributed to a positive UDT across the three categories. Results: Patients with one or more UDTs positive for cannabis were more likely to be discontinued from opioid therapy as a result of the positive UDT compared to those with one or more UDTs positive for nonprescribed prescription medication (adjusted odds ratio [OR] = 18.05, 95% CI = 7.29-44.66). Similarly, patients with UDTs positive for alcohol or illicit substances were more likely to be discontinued for the positive UDTs relative to patients who tested positive for nonprescribed prescription medications (adjusted OR = 13.10, 95% CI = 4.81-35.68). No difference in UDT-related discontinuation decisions was evident between patients with UDTs positive for alcohol/illicit substances versus cannabis (adjusted OR = 1.47, 95% CI = 0.57-3.77). Conclusions: High odds of UDT-related discontinuation were found in patients who tested positive for cannabis, alcohol, or illicit substances, relative to nonprescribed prescription medications.